[
  {
    "ts": "2025-12-05T16:28:46+00:00",
    "headline": "Edwards Lifesciences' Long-term Business Outlook Appears Achievable, RBC Says",
    "summary": "Edwards Lifesciences (EW) reiterated its long-term business outlook on a growing portfolio of struct",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-apos-long-term-162846099.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "bbbb8e09-e98b-3686-8153-f9cd4614e168",
      "content": {
        "id": "bbbb8e09-e98b-3686-8153-f9cd4614e168",
        "contentType": "STORY",
        "title": "Edwards Lifesciences' Long-term Business Outlook Appears Achievable, RBC Says",
        "description": "",
        "summary": "Edwards Lifesciences (EW) reiterated its long-term business outlook on a growing portfolio of struct",
        "pubDate": "2025-12-05T16:28:46Z",
        "displayTime": "2025-12-05T16:28:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-apos-long-term-162846099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-apos-long-term-162846099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-05T19:09:53+00:00",
    "headline": "Edwards Lifesciences (EW): Reassessing Valuation After Upbeat 2025–2026 Outlook and TAVR Growth Signals",
    "summary": "Edwards Lifesciences (EW) used its annual investor day to lift its 2025 revenue outlook and lay out fresh 2026 guidance, reinforcing the case that its TAVR franchise is still doing the heavy lifting. See our latest analysis for Edwards Lifesciences. The guidance bump comes after a strong third quarter and upbeat TAVR data, and the market has taken notice, with an 18.17% year to date share price return and a 1 year total shareholder return of 18.43%, signaling that momentum is building...",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-ew-reassessing-valuation-190953322.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "0f39a0b1-3fba-3b12-8f4c-6fb9af4d9ebf",
      "content": {
        "id": "0f39a0b1-3fba-3b12-8f4c-6fb9af4d9ebf",
        "contentType": "STORY",
        "title": "Edwards Lifesciences (EW): Reassessing Valuation After Upbeat 2025–2026 Outlook and TAVR Growth Signals",
        "description": "",
        "summary": "Edwards Lifesciences (EW) used its annual investor day to lift its 2025 revenue outlook and lay out fresh 2026 guidance, reinforcing the case that its TAVR franchise is still doing the heavy lifting. See our latest analysis for Edwards Lifesciences. The guidance bump comes after a strong third quarter and upbeat TAVR data, and the market has taken notice, with an 18.17% year to date share price return and a 1 year total shareholder return of 18.43%, signaling that momentum is building...",
        "pubDate": "2025-12-05T19:09:53Z",
        "displayTime": "2025-12-05T19:09:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u7koo0rZkPGzBeI1l4rsQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5J1KBMD97NZX1sIZ71qfPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-ew-reassessing-valuation-190953322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-ew-reassessing-valuation-190953322.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]